Airway Management Devices Market presumably crossing the revenue of US$ 1.5 Bn towards 2022 end.

The approximately US$ 1.3 billion market for airway management devices is likely to observe a sluggish pace over next few years, presumably crossing the revenue of US$ 1.5 Bn towards 2022 end. Around half of the market value share is accounted by North America, according to the report.

The FMI analyst also says, “While the airway management space has been witnessing the successful introduction of next-generation endo-bronchial tubes equipped with camera, there is a strong likelihood of fostered product demand for thoracoscopic lung surgeries as well as in robotic surgeries. This and more such technological innovations can potentially uplift the revenue growth scenario of airway management devices market in coming years”.

A senior research analyst at the company says, “The well-known complications and contraindications associated with the use of airway management devices continue to restrict adoption of airway management device types. The subsequent safety concerns are thus leading to frequent product recalls, resulting in the limited growth potential of airway management device landscape at a global level”.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-7775

Explaining the market dynamics further, the analyst says, “The companies are however extending strong efforts towards adapting their products to evolving regulatory guidelines and thereby boosting new product launches. While preventing product recalls will remain in the focal point for manufacturers of airway management devices, they continue to primarily witness sustained demand for anesthesia administration”.

Pre-hospital Settings Are Increasingly Demanding ‘Safer’ Single Use Airway Management Devices

With decently growing demand for emergency medical services and trauma management, the pre-hospital airway management is constantly becoming an imperative segment. With a primary objective to prevent the risks of cross infection, pre-medical settings are generating consistently growing demand for disposable laryngeal masks.

While these airway management devices allow easy insertion and curtail the chances of gastric aspiration, it is more likely that single use airway management devices will witness steady revenue growth in coming years.

FMI Highlights Opportunities for Pediatric Airway Management Devices Manufacturers

In an effort to facilitate the otherwise challenging pediatric airway management, manufacturing companies leading the airway management devices landscape are incorporating an extensive range of cutting-edge technologies in existing devices. The FMI report indicates a chunk of lucrative opportunities residing in the pediatric airway management segment.

  • The Classic Laryngeal Mask Airway (LMA) is currently witnessing notable traction owing to its exceptional efficiency in terms of attaining ventilation in children.
  • The Proseal LMA is likely to enjoy notable adoption in coming years.
  • Recently, Smith Medical launched Protex Bivona FlexTend TTS tracheostomy tubes exclusively for newborns, further covering pediatric patients in the company’s flagship product line.

Segmentation Analysis by FMI at a Glance

  • EndoBronchial tubes hold over 40% share of the current market value, followed by laryngeal masks, reveals the airway management devices market analysis by the type of product. Nasal airway tubes are projected for a relatively positive revenue growth outlook in the near future.
  • Based on the type of usage, single use or disposable airway management devices continue to command over the major market revenue, in contrary to the reusable airway management devices.
  • While hospitals are identified to be accounting for over 45% market revenue share according to the end user analysis, ambulatory surgical centers also hold a sizable share of the total market value.
  • With more than half of the total market value attained through estimated sales of airway management devices, North America continues to govern the global landscape, led by the US reportedly contributing more than US$ 840 Mn to the market in 2022.
  • Western Europe and Asia Pacific are projected to position themselves as the next important regional markets for airway management devices.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-7775

Companies Extend Concerted Efforts on Introducing New ‘Readily Approved’ Products

New product launches currently atop the strategic minds of global leaders in the airway management devices landscape. The key focus area however is to abide by the regulatory standards and achieve approvals in the first go.

Teleflex Incorporated recently announced the launch of LMA Gastro Airway that is a Cuff Pilot Technology-enabled laryngeal mask. While this is the first-ever laryngeal mask that allows facilitated esophageal access, it also promotes the airway control during a range of endoscopic procedures.

M&A Remains a Favored Strategy for an Edge over Competition

Strategic mergers and acquisitions will also remain an important generator of expansion opportunities for leading players in airway management devices market.

Partial acquisition of Airway Medix S.A. by Teleflex Incorporated that completed in the H2 last year had enabled the former to introduce CSS technology-enabled airway management. This advanced technology product innovation has been the company’s important engine for regional market penetration.

Airway management devices market by Category

By Product Type :

  • Laryngeal Masks
  • Tracheostomy Tubes
  • Endotravheal Tubes
  • EndoBronhial Tubes
  • Nasal Airway Tubes
  • Oral Airway Tubes.

By Usage Type :

  • Single Use/ Disposable
  • Reusable

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports : https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs

Allergy Diagnostics Market is expected to grow at an 11.3% CAGR from 2022 to 2032 | FMI

[170 Pages Report] According to ESOMAR-certified Future Market Insights’ (FMI’s) research report, the demand for allergy diagnostics has been increasing significantly due to rising incidence of allergic asthma and food allergies across the globe. As per the study, the global allergy diagnostics market is anticipated to grow at around 11.6% CAGR throughout the forecast period from 2021 to 2031.

According to the report, growing incidence of drug allergies especially from penicillin and morphine has fueled the demand for allergy diagnostics across the globe.

The report also states that increasing air pollution and lack of awareness regarding food and drug allergy in emerging and poor countries are encouraging market players towards developing cost effective allergy diagnostics kits.

According to a report published by the World Health Organization, globally around 262 million people are impacted by asthma out of which 461,000 die from asthma.

Rising demand for effective treatment and addressing causes of asthma will aid the overall expansion of the allergy diagnostics market.

Allergy diagnostics market experienced sluggish growth during the COVID-19 pandemic. This is because the pandemic led to suspension of immunological care and diverted the healthcare professional towards treating COVID patients.

In case of patients with severe asthma or other allergic reaction, virtual care and limited visiting methods were employed to restrict the human contact and stop the virus transmission.

Introduction of cost effective at-home food sensitivity and allergy diagnostic will boost the market growth in upcoming years. Such applications will reduce the burden on hospital and laboratories culminating to reduced allergy diagnostic and medical cost.

In the future, the market is anticipated to grow significantly, as majority of diagnostic laboratories and hospitals are inclining towards automated allergy diagnostics for its high effectiveness. Canada and U.S are likely to yield highly opportunistic prospects, contributing towards the overall expansion of the market.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-4959

Surge in food allergies cases along with increasing incidence of asthma in children will catapult the demand of allergy diagnostics during the forecast period,” says the FMI analyst.

Competitive Landscape

Allergy diagnostics market is highly competitive market owing to presence of global market players. Market players are employing multiple marketing techniques to expand their global outreach.

Allergy diagnostics market players are focusing towards employing organic and inorganic strategies to expand their global foothold.

Inorganic strategies include strategic merger and acquisition and forming an alliance with regional distributors to strengthen their supply chain channels.

They are also emphasizing towards faster product approvals, product development and patenting.

Prominent players operating in the allergy diagnostics market are:

  • Hitachi Chemical Co. Ltd
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers
  • Danaher Corporation
  • HOB Biotech Group Co
  • bioMérieux
  • Hycor Biomedical Inc.
  • Stallergenes Greer
  • R-Biopharm AG
  • Lincoln Diagnostics Inc.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-4959

Key Takeaways from FMI’s Allergy Diagnostics Market Study

  • The U.S is expected to dominate allergy diagnostics market on the back of rising incidence of skin allergies especially eczema and skin inflammation along with high rate of allergic rhinitis (hay fever) in black American population.
  • Presence of advance healthcare infrastructure, favorable government and insurance policies, and increased per capita income are key allergy diagnostics market drivers in Canada.
  • The U.K. will offer lucrative opportunities owing to increasing awareness regarding asthma and other allergic reactions like atopic eczema and hay fever. High prevalence of allergies will fuel the demand of allergy diagnostics in the country.
  • Increasing per capita income and increasing government and private funding towards spreading asthma awareness will boost the allergy diagnostics market sales in China.
  • India has low per capita income and presence of sub-par healthcare system. High prevalence of myths and stigmatic beliefs regarding asthma is one of the main factors limiting the market growth.

More Insights on the Global Allergy Diagnostics Market

In its latest report, FMI offers an unbiased analysis of the global allergy diagnostics market, providing historical data for the period of 2017-2022 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product type (fungal allergy diagnostic and neutral lactase enzymes), by allergen type (inhaled allergens, food allergens, and drug allergens), test type (in-vivo allergy tests and in-vitro allergy tests), and end user (diagnostic laboratories, hospitals, and academic research institutes) across North America, Latin America, Europe, East Asia, South Asia, and Middle East and Africa.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports : https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs

Alzheimer’s Therapeutics Market Is Set to Expand at a CAGR Of 9.3% To reach US$ 6.8 Bn By The Year 2032 : FMI

Alzheimer’s Therapeutics is the most common reason for progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s Therapeutics worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer’s disease.

One in nine people aged 65 and above has Alzheimer’s disease. By 2050, the number of people aged 65 and above affected with Alzheimer’s disease is expected to nearly triple, from 5.2 million to an expected 13.8 million, excluding the development of medical Alzheimer’s Therapeutics advances to avert or cure the disease.

Request Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-14497

A list of Key Players Covered in the Alzheimer’s Therapeutics Market are:

  • AbbVie, Inc.
  • Teva Pharmaceuticals Ltd.
  • Eisai Co., Ltd.
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
  • Novartis AG
  • Zydus Lifesciences Ltd (CADILA)
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd
  • Aurobindo Pharma Ltd
  • Amneal Pharmaceuticals Inc.
  • Macleods Pharmaceuticals Ltd.

The mortality rates due to Alzheimer’s Therapeutics are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased by 14%, 23% and 11%, respectively, while deaths from ALZHEIMER’S THERAPEUTICS increased by 71% in the U.S. Similarly, According to Alzheimer’s Therapeutics International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increase in the demand for Alzheimer’s therapeutics and diagnostics worldwide.

Browse Detailed Summary of Research Report with TOC: https://www.futuremarketinsights.com/reports/alzheimers-therapeutics-market

Population ageing across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in the number of the aged population. In addition, is associated with increased prevalence of chronic diseases like dementia.

Therapies for alzheimer’s therapeutics offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease Alzheimer’s Therapeutics cement. Thus, the magnitude of the affected population and the lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers.

However, the identification of the primary reasons and mechanisms involved in alzheimer’s therapeutics is limited. Drug manufacturers have been unable to validate the significant clinical benefits of treatment for numerous new compounds due to strict regulations. One of the significant trends observed in this market is the collaboration of the existing players.

Customization before Buying, Visit: https://www.futuremarketinsights.com/customization-available/rep-gb-14497

Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates, which is further expected to propel the demand.

The Alzheimer’s Therapeutics and Diagnostics market has seen segmented by therapeutics, diagnostics, imaging technologies and geography. The market for therapeutics includes biomarkers, Cholinesterase inhibitors and NMDA receptor antagonists. Based on diagnostics the market has been segmented into brain imaging and blood tests. The market for imaging technologies includes structural imaging, functional imaging and molecular imaging.

Geographically, the market has been segmented as North America, Europe, Asia Pacific, Latin America, Middle East & Africa and the Rest of the World. North America was observed to be the largest market for Alzheimer’s Therapeutics and Diagnostics due to the increasing prevalence of Alzheimer’s Therapeutics with the rise in the ageing population, and extensive technological Alzheimer’s Therapeutics advancements in the region. With the increase in the ageing population developing region of Asia Pacific, this market is expected to grow at a maximum rate during the forecast period.

Developing countries are expected to offer lucrative opportunities for this market. According to Alzheimer’s Therapeutics International in 2015, 58% of people with dementia live in developing countries, but by 2050 this will rise to 68%. The fastest growth in the elderly population is taking place in China, India, and their south Asian and western Pacific region.

According to World Alzheimer Report in 2015, regional estimations of dementia prevalence in people aged 60 years and over vary from 4.6% in Central Europe to 8.7% in North Africa and the Middle East, however, all other regional estimates fall in a relatively between 5.6% and 7.6%.

Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/14497

The key manufacturers operating in the market are AbbVie Inc., AC Immune SA, Allergan PLC, Amarantus Bioscience Holdings, Anavex LifeSciences, Avid Radiopharmaceuticals, Axon Neuroscience, Axovant Sciences, Daiichi Sankyo Co, Eli Lilly, F. Hoffmann La Roche AG, GE Healthcare, Janssen Pharmaceuticals etc. They have applied strategies, such as mergers & acquisitions, partnerships, joint ventures, agreements, and others to have a strong foothold in the market.

Report by FMI is the outcome of intense study and rigorous assessment of various dynamics shaping the growth of the market. FMI nurtures a close-knit team of analysts, strategists, and industry experts who offer clients tools, methodologies, and frameworks to make smarter decisions. Our objective, insights, and actionable analytics provide CXOs and executives to Alzheimer’s Therapeutics Vance with their mission-critical priorities with confidence.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports : https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs

Optical Coherence Tomography Market is projected to reach US$ 3.0 Bn by 2032 at a CAGR of 9.8%

The size of the worldwide Optical Coherence Tomography Market was estimated at US$ 1.1 billion in 2021 and is anticipated to grow to US$ 1.2 billion in 2022. The overall demand for optical coherence tomography is also expected to increase at an excellent CAGR of 9.8% from 2022 to 2032, reaching over US$ 3.0 Bn by the end of 2032 due to the growing use of optical coherence tomography in clinical and industrial applications.

As per Future Market Insights, the global optical coherence tomography market was valued at over US$ 1.1 Bn in 2021, and is expected to exhibit a CAGR of 9.8% over the forecast period (2022-2032).

Download Sample Copy: https://www.futuremarketinsights.com/reports/sample/rep-gb-3362

Optical coherence tomography systems include widespread applications within the medical, technical and non-medical sectors. With increasing applications, key manufacturers are focusing on innovations to persevere the novel application specifications of their products, thus maintaining a robust portfolio.

Incorporation of automated technology for early disease indication is providing a boost to the development of smart engineered devices. This is set to enhance the overall market value of optical coherence tomography systems.

FMI opines, high cost of equipment establishment and maintenance, as well as the requirement of skilled professionals for operating such systems will act as a restraint to the overall growth of the market.

However, rising research activities on improving various device features to encompass a range of device applications along with the grant of pre-market approvals for such devices and systems is set to promote the sales of OCT systems globally.

Contact our Market Research Specialist: https://www.futuremarketinsights.com/ask-question/rep-gb-3362

Key Takeaways from Market Study

  • Based on product type, fourier domain optical coherence tomography (FD-OCT) systems are expected to hold over 66.6% market value share by the end of 2032.
  • Clinical applications held a market share value of 63.4% in 2021 owing to growing rate of eye disease and need for advanced clinical set up for patients.
  • In terms of scanning speed, the 32000 A-scans/sec segment held maximum market share value of 15.6% in 2021.
  • Healthcare settings held a market share value of 62.7%in 2021 and the trend is likely to continue in the future owing to the growing patient pool within the healthcare settings
  • North America is slated to be the largest leading region with a value share of 44.2% at the end of the forecast period.“Wide applications of OCT systems within the medical sphere has encouraged the adoption of optical coherence tomography systems over the globe” says an analyst of Future Market Insights.

Market Competition

Key companies are rapidly advancing towards the design and development of OCT systems which will promote larger precision and lower time-related analysis of disease during, thus determining accuracy with swift metrics on patient health.

  • In November 2020, NIDEK Co. Ltd. launched a Mirante SLO model with advanced functionality and imaging capabilities.
  • In June 2021, Excelitas Technologies announced the acquisition of PCO AG to expand its portfolio of sensing, illumination, and optical products.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the optical coherence tomography market in its latest study, presenting historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.

Request Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-3362

The research study is based on the product (time-domain (TD-OCT) systems and Fourier domain optical coherence tomography (FD-OCT) Systems (spectral domain-OCT and swept source-OCT)), application (clinical(ophthalmology, cardiovascular, dermatology and dental) and industrial (non-destructive testing, industrial quality control and others)), scanning speed (400 A-scans/sec, 4000 A-scans/sec, 20000 A-scans/sec, 32000 A-scans/sec, 40000 A-scans/sec, 70000 A-scans/sec, 80000 A-scans/sec, 100000 A-scans/sec and 250,000 A-scans/sec), end user (healthcare settings (hospitals, ambulatory surgical centres and specialty clinics), food industry, semiconductor industries, chemical & polymer industries and automotive industry) and across seven key regions of the world.

Key Market Segments Covered in Optical Coherence Tomography Industry Research

By Product:

  • Time-Domain Optical Coherence Tomography (TD-OCT) Systems
  • Fourier Domain Optical Coherence Tomography (FDOCT) Systems
    • Spectral Domain-OCT
    • Swept Source-OCT

By Application:

  • Clinical
    • Ophthalmology
    • Cardiovascular
    • Dermatology
    • Dental
  • Industrial
    • Non-destructive Testing
    • Industrial Quality Control
    • Others

By Scanning Speed:

  • 400 A-scans/sec
  • 4000 A-scans/sec
  • 20000 A-scans/sec
  • 32000 A-scans/sec
  • 40000 A-scans/sec
  • 70000 A-scans/sec
  • 80000 A-scans/sec
  • 100000 A-scans/sec
  • 250,000 A-scans/sec

By End User:

  • Healthcare Settings
    • Hospitals
    • Ambulatory Surgical Centres
    • Specialty Clinics
  • Food Industry
  • Semiconductor Industries
  • Chemical & Polymer Industries
  • Automotive Industry

Top Related Reports:

Intracardiac Imaging Market

Photoacoustic Microscopy Market

Single-use Bioprocessing Probes and Sensors Market

Medical Chairs Market

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

Browse All Reports: https://www.futuremarketinsights.com/reports

LinkedIn| Twitter| Blogs

Injectable Drugs Market Is Expected to reach US$ 937.0 Bn by 2032 | FMI

[341 Pages Report] Cancer, cardiovascular diseases, and metabolic diseases like diabetes, are the main cause of mortality and disability in present times. Even with the understanding of scientific disease indications, it is crucial to elevate diagnosis and control the symptoms and signs of illness.

According to the Future Market Insights’ analysis, the injectable drugs market is set to grow at a 5.8% CAGR over the assessment period. As per the report, the market is projected to be valued at US$ 937.0 Bn by the end of 2032.

Advancements in technologies that involve optimization of the devices used for clinical conditions, be it chronic or acute, clinical innovations, bringing in minimally invasive treatments, and evolvement in clinical diagnostics and management in treating high-risk patients, are the key developments within the general healthcare industry.

To remain ahead of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15073

Demand for related treatments is increasing, as people are now more aware of the right treatment options, doctor-guided plans, and precautionary measures to consider for serious clinical conditions.

Key players in the injectable drugs market are actively seeking to gain approvals from regulatory bodies, and develop products across the continuum of care in severe case recovery. Furthermore, the FDA is expected to approve new devices related to advanced injectable drugs and their administration, over the coming years.

“Increasing incidence of infectious diseases, oncological diseases, cardiac disorders and device innovation are prompting healthcare providers to incorporate new treatment regimens for improved patient outcome,” says an FMI analyst.

Key Takeaways:

  • By product, monoclonal antibodies held the largest share of 5% in the global market in 2021.
  • Based on application, infectious diseases segment held the largest share of 4% in the global market in 2021, with the segment expected to expand at 5.7% CAGR over the forecast period.
  • In terms of molecule, large molecule segment held the largest share of 8% in the global market in 2021.
  • By route of administration, sales in the intravenous (IV) segment are expected to increase at a 3% CAGR over the assessment period.
  • Based on distribution channel, the hospital pharmacies segment was valued at US$ 231.0 Bn in 2021.
  • North America held the largest share of 5% in the global injectable drugs treatment market in 2021, owing to the growing government investments in healthcare and R&D activities.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-15073

Competitive Landscape

Product launches and collaborations with suppliers that have a strong position and are popular in the market are some of the key strategies of the market players operating in the global injectable drugs market. For instance:

  • Merck and Gilead Sciences, Inc. (Gilead) signed an agreement in March 2021 to collaborate on the development and commercialization of long-acting HIV treatments that combine Merck’s investigational nucleoside reverse transcriptase translocation inhibitor islatravir and Gilead’s investigational capsid inhibitor lenacapavir.
  • In March 2022, Sanofi IGM Biosciences, Inc. today announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets. Engineered IgM antibodies represent a new class of potential therapeutics that combine the multi-valency of IgM antibodies possessing 10 binding sites compared to conventional IgG antibodies having only 2 target binding sites.
  • In February 2022, Novartis India Limited extends access to its medicines in India by signing exclusive sales and distribution agreement with Dr. Reddy’s Laboratories

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the injectable drugs market in its latest study, presenting a historical demand assessment of 2014 – 2021 and projections for 2022 – 2032.

The research study is based on the product – (monoclonal antibodies, immunoglobulin, cytokines, insulin, peptide hormones, blood factors, peptide antibiotics, vaccines, small molecule antibiotics, chemotherapy agents, and others), by application (oncology, infectious diseases, diabetes, blood disorders, hormonal disorders, musculoskeletal disorders, CNS diseases, pain management, and cardiovascular diseases), by molecule type (small molecules and large molecules), by route of administration (intravenous (IV), intramuscular (IM), and subcutaneous (SC)), by distribution channel (hospital pharmacies, retail pharmacies, drug stores, and online pharmacies), across seven key regions of the world.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-15073

Key Players :

  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • AstraZeneca Plc
  • Merck & Co., Inc.
  • Viatris + Mylan N.V
  • Cipla Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Samsung Biologics
  • Abbott Laboratories
  • Amgen Incorporated
  • Baxter International Incorporated
  • Becton Dickinson and Company
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline Plc
  • Roche Holding Limited

Key Segments Covered in Injectable Drugs Industry Research

By Product:

  • Monoclonal Antibodies
  • Immunoglobulin
  • Cytokines
  • Insulin
  • Peptide Hormones
  • Blood Factors
  • Peptide Antibiotics
  • Vaccines
  • Small Molecule Antibiotics
  • Chemotherapy Agents
  • Others

By Application:

  • Oncology
  • Infectious Diseases
  • Diabetes
  • Blood disorders
  • Hormonal Disorders
  • Musculoskeletal Disorders
  • CNS Diseases
  • Pain Management
  • Cardiovascular Diseases

By Molecule Type:

  • Small Molecules
  • Large Molecules

By Route of Administration:

  • Intravenous (IV)
  • Intramuscular (IM)
  • Subcutaneous (SC)

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs

Interventional Radiology Market will reach a value of US$ 42.7 Billion by 2032, at a CAGR of 5%

[304 Pages Report] According to the exclusive report of Future Market Insights (FMI), the global interventional radiology market is expected to grow at a CAGR of 5.4% during the forecast period by going up from US$ 24.9 Bn in 2021 to US$ 44.5 Bn market in 2032.

With the increasing cases of several chronic diseases worldwide there has been a growing demand for advanced treatment procedures by the help of Scanners and X-ray vision technologies. These type of interventional radiology glasses and devices not only help in effective treatment of diseases by provide a better scope of early diagnosis rendering it a growing market in recent years.

Introduction of interventional radiology in every level of healthcare facilities has provided the requisite impetus for the rapid growth of interventional radiology that can be witnessed in developing countries as well.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14344

As the non-emergency medical services were abruptly halted during the outbreak of Covid-19 Mandeville in 2020 it had some negative impacts on the growing demand for interventional radiology devices installations.

However, the later discovery of seriousness associated with co-morbid diseases the global interventional radiology market surged with rising introduction of interventional radiology in new healthcare and medical facilities. In the post-pandemic years the application of radiology equipment has grown favouring the interventional radiology service providers.

Several devices equipped with modern technologies such as X-ray systems, MRI Scanners, CT Scanners and other type of medical imaging equipment have dominated the health care sector in recent days.

Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-14344

Key Takeaways

  • By 20221, Cardiology Segment was valued at US$ 7.7 Bn in terms of revenue contributed the global interventional radiology market.
  • The Gastroenterology segment is poised to record a higher growth projection during the forecast years reaching a value of more than US $ 2 Bn by 2028.
  • Among several procedures angioplasty segment will expected to grow at a CAGR of 5.8% during the forecast period.
  • US market dominates the interventional radiology for medical students having a net worth of more than US$ 8 Bn.
  • In Europe, Germany is the prominent region for the interventional radiology market players valued at US$ 1.5 Bn in terms of revenue generated.

Competitive Landscape

Carestream Health Inc., Hologic Inc., GE Healthcare, Fujifilm Corporation, Samsung Healthcare (Samsung Electronics Co., Ltd.), Shimadzu Corporation, Siemens Healthineers, Canon Medical Systems Corporation, and Olympus Corporation are some of the prominent players of the global interventional radiology market covered by the market analysis report.

A large number of local players have occupied the market by supplying equipments related to interventional radiology for medical student’s requirements.

  • In the field of ultrasound, digital radiography and computed tomography Samsung Healthcare, a subsidiary of Samsung Electronics Co., Ltd, launched a premium product for diagnostic imaging solutions in December 2020. This initiative for ultrasound guided interventional procedures carried out at Radiology Society of North America (RSNA) 2020 assisted the company in expanding their product portfolio in North America and beyond.

Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-14344

  • Canon Medical launched an upgraded product under the Aquilion ONE/PRISM Edition by the name of One-Beat Spectral Cardiac CT in November 2020. THE Aquillion Edition assisted with deep learning spectral capabilities is a major development in the field of cardiac exam and after interventional radiology glasses.
  • GE Healthcare division of General Electrical Company launched an advanced ultrasound system by the name of LOGIQ E10 in March 2018. This system has been equipped with comprehensive tools that can provide treatment for a wife range of diseases and remote control applications to improve efficiency.

Key Segments

By Product:

  • MRI Systems
  • CT Scanners
  • Ultrasound Imaging Systems
  • Angiography Systems
  • Others

By Procedure:

  • Angioplasty
  • Biopsy
  • Embolization
    • Peripheral Embolization
    • Prostatic Artery Embolization
    • Genicular Artery Embolization
    • Fibroid
    • Others
  • Thrombolysis
  • Vertebroplasty
  • Nephrostomy
  • Interventional Oncology
  • MSK Intervention
  • Others

By End User:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Others

By Application:

  • Cardiology
  • Oncology
  • Urology
  • Gastroenterology
  • Obstetrics
  • Gynaecology
  • Others

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs

Agricultural Grade Zinc Chemicals Market Size, Share 2032: Present Scenario and Growth Prospects

The global agricultural grade zinc chemicals market is estimated to garner US$ 1.3 Billion while exhibiting a 5.4% CAGR during the forecast period. The growing support from several governments is likely to fuel the market growth in the coming years. The industry is expected to secure US$ 760.0 Million in 2022.

Growth and expansion of the agricultural industry especially in the developing economies, the development of fertilizers will create lucrative opportunities for growth of the agriculture grade zinc chemicals market. Also, the rising number of research and development by the leading manufacturer and the use of zinc chemicals in agriculture is the primary factor driving the growth of the agricultural grade zinc chemicals market.

The chemical fertilizer segment is likely to offer remunerative opportunities for the global agricultural grade zinc chemicals market. Several emerging economies are making significant developments in their agricultural sector, thereby, providing lucrative opportunities to players in the market.

Get 30% Discount Before it’s Gone – Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14853

Key Takeaways:

  • By application, the chemical fertilizer segment is expected to record a 5.4% CAGR by 2032
  • By type, the zinc sulphate segment to expand at a 5.3% growth rate during the forecast period
  • The U.S market to garner US$ 462.2 Million and record a 5.2% CAGR from 2022-2032
  • Market in China to procure US$ 92.9 Million, expanding at a 4.8% growth rate during the assessment period

Growth and expansion of agricultural industry especially in the developing economies, and development in fertilizers, is expected to fuel the demand of agricultural grade zinc chemicals market over the forecast period,” says an FMI analyst.

Competitive Landscape

Eminent players of the global agricultural grade zinc chemicals market include UPL, Syngenta Crop Protection AG, IFFCO, Yara, and Zochem Inc. among others.  Recent developments among players include:

  • In June 2020 – IFFCO signed MoU with ICAR for collaborative research, testing & extension programs across the country for collaborative research, testing and validation of different products through ICAR institutes and Krishi Vigyan Kendras (KVKs). This will also enable these centers to disseminate technological advancements by imparting training, through awareness programs, campaigns, field trials and demonstrations for the benefit of farmers.
  • In May 2021 – Yara, a leading crop nutrition solutions provider, announced the commercial launch of Agoro Carbon Alliance, a global business created for farmers to earn additional revenue from positive climate action. By adopting climate-positive practices farmers can produce Farm Carbon Credits or climate-smart certified crops and help to decarbonize food supply chains.

Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-14853

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global agricultural grade zinc chemicals market presenting a historical analysis from 2015 to 2021 and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of Type (Zinc Oxide, Zinc sulphate, EDTA chelated zinc, Sulphur Zinc Bentonite, Zinc chloride, Other), by Application(Animal feed, chemical fertilizer, others), and Region (North America, Europe, APAC, Middle East & Africa, and Latin America)

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Unit No: 1602-006
Jumeirah Bay 2
Plot No: JLT-PH2-X2A
Jumeirah Lakes Towers
Dubai
United Arab Emirates
LinkedInTwitterBlogs
For Sales Enquiries: sales@futuremarketinsights.com
Browse latest Market Reports: https://www.futuremarketinsights.com/category/chemicals-and-materials

 

Injectable Drugs Market with revenue expected to reach US$ 840.8 Mn by 2031 | FMI

[341 Pages Report] Cancer, cardiovascular diseases, and metabolic diseases like diabetes, are the main cause of mortality and disability in present times. Even with the understanding of scientific disease indications, it is crucial to elevate diagnosis and control the symptoms and signs of illness.

According to the Future Market Insights’ analysis, the injectable drugs market is set to grow at a 5.8% CAGR over the assessment period. As per the report, the market is projected to be valued at US$ 937.0 Bn by the end of 2032.

Advancements in technologies that involve optimization of the devices used for clinical conditions, be it chronic or acute, clinical innovations, bringing in minimally invasive treatments, and evolvement in clinical diagnostics and management in treating high-risk patients, are the key developments within the general healthcare industry.

To remain ahead of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15073

Demand for related treatments is increasing, as people are now more aware of the right treatment options, doctor-guided plans, and precautionary measures to consider for serious clinical conditions.

Key players in the injectable drugs market are actively seeking to gain approvals from regulatory bodies, and develop products across the continuum of care in severe case recovery. Furthermore, the FDA is expected to approve new devices related to advanced injectable drugs and their administration, over the coming years.

“Increasing incidence of infectious diseases, oncological diseases, cardiac disorders and device innovation are prompting healthcare providers to incorporate new treatment regimens for improved patient outcome,” says an FMI analyst.

Key Takeaways:

  • By product, monoclonal antibodies held the largest share of 5% in the global market in 2021.
  • Based on application, infectious diseases segment held the largest share of 4% in the global market in 2021, with the segment expected to expand at 5.7% CAGR over the forecast period.
  • In terms of molecule, large molecule segment held the largest share of 8% in the global market in 2021.
  • By route of administration, sales in the intravenous (IV) segment are expected to increase at a 3% CAGR over the assessment period.
  • Based on distribution channel, the hospital pharmacies segment was valued at US$ 231.0 Bn in 2021.
  • North America held the largest share of 5% in the global injectable drugs treatment market in 2021, owing to the growing government investments in healthcare and R&D activities.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-15073

Competitive Landscape

Product launches and collaborations with suppliers that have a strong position and are popular in the market are some of the key strategies of the market players operating in the global injectable drugs market. For instance:

  • Merck and Gilead Sciences, Inc. (Gilead) signed an agreement in March 2021 to collaborate on the development and commercialization of long-acting HIV treatments that combine Merck’s investigational nucleoside reverse transcriptase translocation inhibitor islatravir and Gilead’s investigational capsid inhibitor lenacapavir.
  • In March 2022, Sanofi IGM Biosciences, Inc. today announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets. Engineered IgM antibodies represent a new class of potential therapeutics that combine the multi-valency of IgM antibodies possessing 10 binding sites compared to conventional IgG antibodies having only 2 target binding sites.
  • In February 2022, Novartis India Limited extends access to its medicines in India by signing exclusive sales and distribution agreement with Dr. Reddy’s Laboratories

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the injectable drugs market in its latest study, presenting a historical demand assessment of 2014 – 2021 and projections for 2022 – 2032.

The research study is based on the product – (monoclonal antibodies, immunoglobulin, cytokines, insulin, peptide hormones, blood factors, peptide antibiotics, vaccines, small molecule antibiotics, chemotherapy agents, and others), by application (oncology, infectious diseases, diabetes, blood disorders, hormonal disorders, musculoskeletal disorders, CNS diseases, pain management, and cardiovascular diseases), by molecule type (small molecules and large molecules), by route of administration (intravenous (IV), intramuscular (IM), and subcutaneous (SC)), by distribution channel (hospital pharmacies, retail pharmacies, drug stores, and online pharmacies), across seven key regions of the world.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-15073

Key Players :

  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • AstraZeneca Plc
  • Merck & Co., Inc.
  • Viatris + Mylan N.V
  • Cipla Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Samsung Biologics
  • Abbott Laboratories
  • Amgen Incorporated
  • Baxter International Incorporated
  • Becton Dickinson and Company
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline Plc
  • Roche Holding Limited

Key Segments Covered in Injectable Drugs Industry Research

By Product:

  • Monoclonal Antibodies
  • Immunoglobulin
  • Cytokines
  • Insulin
  • Peptide Hormones
  • Blood Factors
  • Peptide Antibiotics
  • Vaccines
  • Small Molecule Antibiotics
  • Chemotherapy Agents
  • Others

By Application:

  • Oncology
  • Infectious Diseases
  • Diabetes
  • Blood disorders
  • Hormonal Disorders
  • Musculoskeletal Disorders
  • CNS Diseases
  • Pain Management
  • Cardiovascular Diseases

By Molecule Type:

  • Small Molecules
  • Large Molecules

By Route of Administration:

  • Intravenous (IV)
  • Intramuscular (IM)
  • Subcutaneous (SC)

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs

Insulin Delivery Pens Market is projected to reach over US$ 9,100 Million by the end of 2027

Global Insulin Delivery Pens Market: Dynamics

Several factors contribute to the growth of the global insulin delivery pens market. One major driver is the move towards value based compensation models for therapies from unit priced payment models that are more commonly used to self-administer treatment for chronic diseases like diabetes. The shift is prominently seen in regions such as U.S. and Europe. This shift, in turn, results in increased demand for technology driven insulin delivery systems with higher levels of accuracy and patient compliance in addition to providing patients with the necessary coaching and education. The demand for smart insulin pens has also increased globally as healthcare stakeholders seek to gather useful information from clinical trials and the real world environment. Also, diabetes being chronic and a very expensive disease, people look for options to reduce the expenses related to the regular check-ups of diabetes. Smart insulin pens help patients keep a check on their diabetes with all the necessary dosage data pertaining to the disease and its effective management.

Insulin pens are used as an effective solution for diabetes management. With the current technological advancements, insulin now comes with different variants like reusable pens that can be used by just loading insulin cartridges available in packs. Disposable insulin pens contain a prefilled cartridge and the entire pen is disposed or thrown away providing convenient delivery of insulin. Smart insulin pens are the latest advancement in diabetes management.  These smart insulin pens are either Bluetooth enabled wireless devices allowing automatic data sharing or devices that require data sharing with a dedicated USB data cable. These pens also come with a feature incorporating a clinician configured bolus calculator with the ability to deliver multiple insulin doses every day safely and discreetly. A new research report by Future Market Insights titled ‘Insulin Delivery Pens Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027) gives an overview of the global insulin delivery pens market along with a comprehensive market forecast for the period 2017-2027.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-5605

Global Insulin Delivery Pens Market: Segmental Highlights

The global insulin delivery pens market is segmented into various segments based on product type, indication, distribution channel and region. The report presents the analysis of every market segment along with the yearly growth rate, revenue share and pricing analysis. Some of the key segmental highlights from the report are as under:

  • Among the regional markets, North America is expected to emerge the dominating market in terms of revenue, with a market value of almost US$ 2,000 Mn in 2017 and an estimated market value reaching over US$ 5,500 Mn by the end of forecast period in 2027.
  • In the product type segmentation, the reusable insulin pens segment is anticipated to dominate the market in terms of revenue share. Within the reusable insulin pens segment, refillable insulin pens is projected to stay at a high market valuation throughout the forecast period, reaching an estimated US$ 9,183.0 Mn by 2027 end at a CAGR of 10.2%.
  • By indication, the market is categorised into Diabetes Type 1 and Diabetes Type 2, among which the Diabetes Type 2 segment leads the market with a market valuation expected to reach over US$ 12,300 Mn by the end of 2027, growing at a CAGR of 10.5% during the forecast period.
  • In the distribution channel category, the hospital pharmacy segment is expected to remain dominant, with a market value of over US$ 1,900 Mn in 2017. This segment is in close competition with the online sales segment, which is ahead of the hospital pharmacy segment in terms of CAGR, with a growth rate of 11.7% during the forecast period.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-5605

Global Insulin Delivery Pens Market: Competitive Landscape

This research report includes a brief profile of some of the major players in the global insulin delivery pens market. These descriptive profiles provide information on the overall development of the companies along with their future strategies. Some of the companies featured in the report are Sanofi S.A., Companion Medical, Inc., Patients Pending Ltd, Diamesco Co., Ltd., DiabNext, Owen Mumford Ltd, and Emperra GmbH E-Health Technologies.

Key SegmentIndication

  • Diabetes Type I
  • Diabetes Type II

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales
  • Diabetes Clinics

Region

  • North America
  • Western Europe
  • Eastern Europe
  • Latin America
  • APEJ
  • Japan
  • MEA

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-5605

Product Type

  • Reusable Insulin Pens
    • Refillable Insulin Pens
    • Bluetooth Connected Smart Insulin Pens
    • USB Connected Smart Insulin Pens
  • Disposable Insulin Pens
  • Smart Insulin Pen Caps

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Unit No: 1602-006
Jumeirah Bay 2
Plot No: JLT-PH2-X2A
Jumeirah Lakes Towers
Dubai
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs

Metalworking Fluids Market Global Industry Overview and Competitive Landscape till 2031

As per a latest market study by Future Market Insights (FMI), the demand for metalworking fluids is projected to grow at 3.7% CAGR between 2021 and 2031, reaching US$ 9.61 Bn in 2021.  With a favorable demand outlook, sales of metalworking fluids are poised to total 36,67,557.1 Tons by 2031.

Increasing adoption of metalworking fluids for the production of key metal components in the transportation equipment and heavy machinery industries will continue augmenting market growth.

Growing preference for lightweight metals such as aluminum, copper, and zinc in production of complex components used in high performance applications is anticipated to boost sales of metalworking fluids over the forecast period.

Get a Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-517

Rapid urbanization and population growth are leading to a surge in demand for private transportation vehicle and increased spending on public transport. The automotive industry has been a key beneficiary of this trend, as automotive sales continued increasing in developing countries such as China, India, Saudi Arabia, and ASEAN nations.

Similar growth has been recorded in these markets for public transportation facilities such as metro trains, resulting in high demand for metalworking fluids in the automotive and transportation sectors.

However, various stringent regulations regarding the usage of harmful synthetic chemicals are restricting the market growth. To counter this issue, manufacturers are investing in research and development activities to develop eco-friendly lubrication solutions.

Emergence of bio-based fluids, and other multifunctional fluids to reduce incompatibility will continue providing tailwinds to metalworking fluids sales in the forthcoming years.

Key Takeaways from Metalworking Fluids Market Study

  • Transportation equipment is the leading consumer of metalworking fluids, accounting for and more than half of the overall metalworking fluids produced.
  • Sales of straight oils are projected to increase by 3.1% year-over-year in 2021.
  • Based on product type, sales of metal removal fluids are projected to command over 50% of the total metalworking fluids market share.
  • The U.S. will continue dominating the North America metalworking fluids market, growing by 3.0% year-over-year rate in 2021.
  • Demand for metalworking fluids in Germany is anticipated to rise at a 3.5% CAGR through 2031.
  • China will emerge as a lucrative metalworking fluids market, expanding at a 5.1% CAGR over the forecast period.
  • Japan and South Korea will collectively account for 9.7% of the total metalworking fluids market share.

“Increasing sales of lightweight automotive such as electronic vehicles (EVs), along with innovations in fluid blends to cater to diverse industrial requirements will continue pushing the sales of metalworking fluids over the forecast period,” says the FMI analyst.  

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-517

Metalworking Fluids Market: Participant Insights                                               

Key players operating in the global metalworking fluids market comprise ExxonMobil Corporation, Idemitsu Kosan Co. Ltd., Quaker Chemical Corporation, FUCHS Petrolub SE, TotalEnergies SE, Apar Industries Limited, Yushiro Chemical Industry Co. Ltd., Cimcool Industrial Products LLC, and Metalworking Lubricants Company.

As per FMI’s analysis, top 5 players including Quaker Chemical Corporation, ExxonMobil Corporation, TotalEnergies SE, Idemitsu Kosan Co. Ltd. and BP plc. are projected to account for 45-55% of the total metalworking fluid market share.

In efforts to gain a competitive edge, leading players are focusing on research and development to launch new and innovative products that are more efficient and comply with various stringent regulations. In addition to this, collaborations, mergers, and acquisitions will remain effective growth strategies among players over the assessment period.  For instance:

  • In 2021, Quaker Chemical Corporation announced the beginning of a new joint venture with Grindaix GmbH, which is a German provider of high-tech coolant control solutions and delivery systems.
  • In 2021, Idemitsu and IHI Corporation announced that they had concluded a joint agreement to establish a supply chain network for ammonia.

Feel free to ask your queries @ https://www.futuremarketinsights.com/ask-question/rep-gb-517

More Insights into the Metalworking Fluids Market Report

In its latest report, FMI offers an unbiased analysis of the global metalworking fluids market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of category (straight oil, emulsified oil, semi-synthetic oil, and synthetic oil), product type (removal fluid, protection fluids, forming fluids, and treating fluids) end-use type (metal fabrication, heavy machinery, transportation equipment, and general manufacturing) and across seven regions (North America, Latin America, Eastern Europe, Western Europe, Asia Pacific excluding Japan (APEJ), Japan, and Middle East & Africa).

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Unit No: 1602-006
Jumeirah Bay 2
Plot No: JLT-PH2-X2A
Jumeirah Lakes Towers
Dubai
United Arab Emirates
LinkedInTwitterBlogs
For Sales Enquiries: sales@futuremarketinsights.com
Browse latest Market Reports: https://www.futuremarketinsights.com/category/chemicals-and-materials